AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 161 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2015. The put-call ratio across all filers is 1.31 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $1,069,000 | -32.4% | 25,623 | -14.4% | 0.00% | -50.0% |
| Q3 2016 | $1,581,000 | +62.8% | 29,935 | +29.2% | 0.00% | +100.0% |
| Q2 2016 | $971,000 | +142.8% | 23,176 | +135.2% | 0.00% | 0.0% |
| Q1 2016 | $400,000 | -51.0% | 9,853 | -21.6% | 0.00% | 0.0% |
| Q4 2015 | $816,000 | -7.4% | 12,567 | +0.6% | 0.00% | 0.0% |
| Q3 2015 | $881,000 | -44.8% | 12,487 | -13.1% | 0.00% | -50.0% |
| Q2 2015 | $1,597,000 | -73.4% | 14,368 | -77.4% | 0.00% | -75.0% |
| Q1 2015 | $6,008,000 | -14.5% | 63,716 | +1.6% | 0.01% | -11.1% |
| Q4 2014 | $7,026,000 | +108.4% | 62,710 | +14.1% | 0.01% | +80.0% |
| Q3 2014 | $3,371,000 | +60.9% | 54,939 | +20.2% | 0.01% | +66.7% |
| Q2 2014 | $2,095,000 | +171.4% | 45,714 | +131.8% | 0.00% | +200.0% |
| Q1 2014 | $772,000 | +70.8% | 19,718 | +4.6% | 0.00% | 0.0% |
| Q4 2013 | $452,000 | -14.9% | 18,858 | -0.6% | 0.00% | 0.0% |
| Q3 2013 | $531,000 | – | 18,978 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
| Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
| Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
| BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
| Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
| Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
| Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
| BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
| Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
| HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |